THE EFFICACY OF THE PEGINTERFERON TREATMENT IN CHRONIC HEPATITIS HDV AND COMPENSATE LIVER CIRRHOSIS
Abstract
Aim: to evaluate the efficiency of the treatment with Peginterferon alfa 2a 180 mcg/week, 48 weeks in patients with chronic hepatitis or compensated liver cirrhosis HDV and predictive factors of response to treatment. Material and methods: prospective study that enrolled 50 patients with chronic hepatitis or compensated cirrhosis HDV between the 1st of January 2011 – 3st of December 2011. The diagnosis of chronic HDV infection was made based on the presence of detectable anti HDV IgG antibodies and HDV-RNA. Patients were evaluated at baseline by CBC, liver function tests, HBV profile, HDV RNA, and by liver biopsy/Fibrotest for evaluating fibrosis and necroinflamatory activity. At 24 weeks CBC (count blood cells), liver function tests, quantitative HBsAg and at 48 and 72 weeks biochemical tests, HDV RNA, HBV DNA, quantitative HBsAg, were performed. Adverse reactions to the treatment were recorded. Results: SVR (sustained virologic response) was recorded in 12 patients (24%) and biochemical response in 28 patients (56%). SVR was correlated with low-grade fibrosis, age, the aminotransferase value and the value of HBsAg at the beginning of the treatment. In week 48 HDV RNA was undetectable in 20 patients (40%). The therapy was well tolerated, except two patients for whom the discontinuation of the treatment was decided for severe exacerbation of cytolysis, respectively hepatic decompensation. Conclusions: In a representative group of patients, the treatment with Peginterferon once again proves its efficacy in treating chronic HDV.
References
2. L Gheorghe, S .Iacob, I.Simionov et al. Natural history of compensated viral B and D cirrhosis. Ro-manian J Gastroenterol 2005: 14(4): 329-335.
3. Gunsar F. Treatment of delta hepatitis. Expert Rev Anti Infe Ther 2013; 11(5): 489-498.
4. Rizzetto M. Hepatitis D: thirty yers after. J.Hepatol 2009; 50(5): 1043-1050.
5. Janssen HLA, Brouwer JT, Nevens F, et al. Fatal hepatic decompensation associated with interferon alfa. BMJ 1993; 306: 107-108.
6. Flink HJ, Sprengers D, Hansen BE, et al. Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg interferon (alpha)-2b therapy. Gut 2005; 54: 1604-1609.
7. Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatol 2010; 52:1251-1257.
8. Niro GA, Ciancio A, Gaeta GB, Smedile A, Marrone A, Olivero A, et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatol 2006; 44: 713-720.
9. Wedemeyer H, Yurdaydìn C, Dalekos GN, Erhardt A, Çakaloğlu Y, Değertekin H et al.. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011; 364: 322-33.
10. Erhardt A, Gerlich W, Starke C, Wend U, Donner A, Sagir A, Heintges T, Häussinger D. Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. Liver Int 2006; 26: 805-810.
11. Castelnau C, Le Gal F, Ripault MP, Gordien E, Martinot-Peignoux M, Boyer N, Pham BN, Maylin S, Bedossa P, Dény P, Marcellin P, Gault E. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatol 2006; 44: 728-735.
12. Zachou K, Yurdaydin C, Drebber U, Dalekos GN, Erhardt A, Cakaloglu Y, et al. Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. Liver Int 2010; 30: 430-437.
13. Rosina F, Pintus C, Meschievitz C, Rizzetto M. A randomized controlled trial of a 12-month course of recombinant human interferon-alpha in chronic delta (type D) hepatitis: a multicenter Italian study. Hepatol 1991; 13: 1052-1056.
14. Yurdaydin C, Bozkaya H, Onder FO, et al. Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon. J Viral Hepat 2008; 15: 314–321.
15. Marzano A, Ottobrelli A, Spezia C, Daziano E, Soranzo ML, Rizzetto M. Treatment of early chronic delta hepatitis with lymphoblastoid alpha interferon: a pilot study. Ital J Gastroenterol 1992; 24: 119–121.
16. Hughes S, Carey I, Shang D, et al. Hepatitis delta virus RNA level and IgM antibody titer predict response to Peg-interferon therapy (abstract). Hepatol 2009; 50(Suppl. 4): 735A.
17. Yurdaydin C, Kabacam G, Cakaloglu Y, et al. Efficacy of pegylated interferon 0[based treatment in patients with cirrhosis due to chronic delta hepatitis: comparison with non-cirrhotic patients (abstract). Hepatol 2009; 50(Suppl. 4): 736A.
18. Farci P, Mandas A, Coiana A, et al.Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med 1994; 330: 88–94.

Additional Files
Published
Issue
Section
License
COPYRIGHT
Once an article is accepted for publication, MSJ requests a transfer of copyrights for published articles.
COPYRIGHT TRANSFER FORM FOR
REVISTA MEDICO-CHIRURGICALĂ A SOCIETĂȚII DE MEDICI ȘI NATURALIȘTI DIN IAȘI /
THE MEDICAL-SURGICAL JOURNAL OF THE SOCIETY OF PHYSICIANS AND NATURALISTS FROM IASI
We, the undersigned authors of the manuscript entitled
_____________________________________________________________________________________
_____________________________________________________________________________________
warrant that this manuscript, which is submitted for publication in the REVISTA MEDICO-CHIRURGICALĂ, has not been published and it is not under consideration for publication in another journal.
- we give the consent for publication in the REVISTA MEDICO-CHIRURGICALĂ, in printed and electronic format and we transfer unconditioned and complete the copyright of this manuscript to the REVISTA MEDICO-CHIRURGICALĂ, in the event of its acceptance.
- the manuscript does not break the intellectual property rights of any other person.
- we have read the submitted version of the manuscript and we are fully responsible for the content.
Names and signatures of authors / copyright owners (the following sequence is the authorship of the article):
- ______________________________/_________________________
- ______________________________/_________________________
- ______________________________/_________________________
N.B. All the authors must sign this form